Every record from Medutest · page 3
Fast turnaround and the widest compound acceptance, at unit mass resolution rather than high resolution. Measured offset against the reference laboratory is +0.065 pp on 517 paired lots. Full laboratory profile →
| Report | Compound | Supplier | Lot | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|---|
| AX-2026-041630 | BPC-157 | QSC | QSC-2511-N8732 | 2026-Q2 | 99.70 | 5.69 | 105.9 | Supplier-supplied | 1 | MARGINAL |
| AX-2026-042581 | SLU-PP-332 | GGPeps | GGPE-2511-R8569 | 2026-Q2 | 98.80 | 4.69 | 106.1 | Supplier-supplied | 1 | MARGINAL |
| AX-2026-042592 | Tirzepatide | GGPeps | GGPE-2604-H8313 | 2026-Q2 | 98.45 | 2.46 | 105.7 | Buyer-sourced | 1 | MARGINAL |
| AX-2026-042023 | Ipamorelin | TFC | TFC-2603-M6766 | 2026-Q2 | 99.70 | 4.52 | 99.0 | Supplier-supplied | 1 | MARGINAL |
| AX-2026-041529 | BPC-157 | QYB | QYB-2601-H6381 | 2026-Q2 | 99.85 | 2.17 | — | Supplier-supplied | 1 | MARGINAL |
| AX-2026-042409 | MK-677 (Ibutamoren mesylate) | SWB | SWB-2605-B4738 | 2026-Q2 | 99.32 | 2.99 | 94.9 | Laboratory-retained | 1 | FAIL |
| AX-2026-042629 | BPC-157 | GGPeps | GGPE-2602-E8672 | 2026-Q2 | 98.91 | 5.04 | 101.9 | Laboratory-retained | 1 | MARGINAL |
| AX-2026-043146 | Enclomiphene citrate | SSA | SSA-2603-C6950 | 2026-Q2 | 97.92 | 3.11 | 92.9 | Buyer-sourced | 2 | FAIL |
| AX-2026-041890 | Melanotan II | JEEP | JEEP-2604-R3923 | 2026-Q2 | 99.80 | 5.06 | 107.4 | Supplier-supplied | 1 | FAIL |
| AX-2026-042590 | Tirzepatide | GGPeps | GGPE-2604-H8313 | 2026-Q2 | 99.38 | 1.72 | — | Supplier-supplied | 1 | MARGINAL |
| AX-2026-042870 | BPC-157 | GGPeps | GGPE-2512-G2285 | 2026-Q2 | 98.80 | 3.03 | 100.5 | Supplier-supplied | 2 | MARGINAL |
| AX-2026-042753 | 5-Amino-1MQ | GGPeps | GGPE-2512-M9695 | 2026-Q2 | 99.21 | 4.61 | 93.5 | Supplier-supplied | 2 | FAIL |
| AX-2026-042598 | Tirzepatide | GGPeps | GGPE-2604-H8313 | 2026-Q2 | 99.39 | 2.06 | 106.1 | Supplier-supplied | 1 | MARGINAL |
| AX-2026-042694 | Retatrutide | GGPeps | GGPE-2512-D9394 | 2026-Q2 | 98.17 | 3.85 | — | Supplier-supplied | 1 | MARGINAL |
| AX-2026-042759 | TB-500 | GGPeps | GGPE-2601-B9932 | 2026-Q2 | 99.82 | 4.94 | 89.3 | Supplier-supplied | 1 | MARGINAL |
| AX-2026-041622 | BPC-157 | QSC | QSC-2511-N8732 | 2026-Q2 | 99.93 | 5.50 | 89.4 | Supplier-supplied | 2 | MARGINAL |
| AX-2026-041368 | Semaglutide | WWB | WWB-2512-T3671 | 2026-Q2 | 99.03 | 2.44 | 96.7 | Supplier-supplied | 1 | MARGINAL |
| AX-2026-041811 | Tirzepatide | FGP | FGP-2605-R1831 | 2026-Q2 | 98.09 | 6.21 | 89.8 | Supplier-supplied | 3 | MARGINAL |
| AX-2026-041704 | Hexarelin | QSC | QSC-2601-N9656 | 2026-Q2 | 99.74 | 6.27 | — | Supplier-supplied | 1 | MARGINAL |
| AX-2026-041534 | BPC-157 | QYB | QYB-2601-H6381 | 2026-Q2 | 99.93 | 1.73 | — | Supplier-supplied | 1 | MARGINAL |
| AX-2026-042297 | AOD-9604 | HJ | HJ-2601-N2483 | 2026-Q2 | 99.00 | 4.72 | 99.5 | Supplier-supplied | 1 | MARGINAL |
| AX-2026-043185 | PT-141 (Bremelanotide) | GL Biochem | GLBI-2511-F8417 | 2026-Q2 | 98.47 | 2.58 | — | Supplier-supplied | 2 | FAIL |
| AX-2026-042152 | Tirzepatide | Homopeptide | HOMO-2601-N9196 | 2026-Q2 | 99.14 | 5.39 | — | Supplier-supplied | 2 | MARGINAL |
| AX-2026-043564 | GHRP-6 | BCH | BCH-2603-Y7018 | 2026-Q2 | 98.44 | 4.83 | — | Buyer-sourced | 1 | FAIL |
| AX-2026-041395 | Adipotide | WWB | WWB-2512-R4093 | 2026-Q2 | 99.20 | 3.03 | — | Supplier-supplied | 2 | MARGINAL |
| AX-2026-043526 | MK-677 (Ibutamoren mesylate) | BCH | BCH-2511-G7276 | 2026-Q2 | 97.60 | 4.50 | — | Buyer-sourced | 1 | FAIL |
| AX-2026-043235 | Melanotan II | SGN | SGN-2602-L1809 | 2026-Q2 | 99.41 | 3.06 | 102.3 | Supplier-supplied | 1 | MARGINAL |
| AX-2026-042160 | GHRP-2 | Homopeptide | HOMO-2602-E9033 | 2026-Q2 | 99.62 | 4.50 | 99.5 | Supplier-supplied | 1 | MARGINAL |
| AX-2026-041820 | PT-141 (Bremelanotide) | FGP | FGP-2602-Y1702 | 2026-Q2 | 99.93 | 3.89 | 96.6 | Supplier-supplied | 0 | PASS |
| AX-2026-041661 | Semaglutide | QSC | QSC-2511-M9226 | 2026-Q2 | 99.44 | 3.77 | 100.0 | Supplier-supplied | 1 | MARGINAL |
| AX-2026-043452 | BPC-157 | WXT | WXT-2602-W4680 | 2026-Q2 | 97.91 | 5.16 | — | Buyer-sourced | 1 | FAIL |
| AX-2026-042028 | Ipamorelin | TFC | TFC-2603-M6766 | 2026-Q2 | 99.93 | 5.82 | — | Supplier-supplied | 1 | FAIL |
| AX-2026-041776 | SS-31 (Elamipretide) | FGP | FGP-2601-R1916 | 2026-Q2 | 99.93 | 3.97 | — | Supplier-supplied | 0 | PASS |
| AX-2026-041620 | BPC-157 | QSC | QSC-2511-N8732 | 2026-Q2 | 99.93 | 5.41 | — | Supplier-supplied | 1 | MARGINAL |
| AX-2026-041307 | Ipamorelin | WWB | WWB-2604-E3153 | 2026-Q2 | 99.72 | 5.93 | 97.0 | Supplier-supplied | 1 | MARGINAL |
| AX-2026-043276 | Hexarelin | CPC | CPC-2511-F1491 | 2026-Q2 | 98.22 | 5.17 | — | Laboratory-retained | 2 | FAIL |
| AX-2026-043248 | BPC-157 | SGN | SGN-2512-H1950 | 2026-Q2 | 98.55 | 4.99 | 94.3 | Supplier-supplied | 2 | MARGINAL |
| AX-2026-042749 | Cagrilintide | GGPeps | GGPE-2603-R9581 | 2026-Q2 | 97.95 | 6.05 | — | Supplier-supplied | 1 | FAIL |
| AX-2026-042635 | Semaglutide | GGPeps | GGPE-2603-W8751 | 2026-Q2 | 99.93 | 4.06 | 100.0 | Supplier-supplied | 2 | MARGINAL |
| AX-2026-043050 | Hexarelin | KP | KP-2604-X5435 | 2026-Q2 | 98.56 | 3.25 | 104.3 | Supplier-supplied | 3 | FAIL |